p44/42 MAPK antibody | knockout validation | Cell Signaling Technology 9102
DOI
//dx.doi.org/10.13070/ko.en.6.1794
Date
2016-11-08

This is a knockout-validated antibody summary, based on the publication "FGF stimulation of the Erk1/2 signalling cascade triggers transition of pluripotent embryonic stem cells from self-renewal to lineage commitment", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

Antibody information

rabbit polyclonal

Company: Cell Signaling Technology

Antibody: P44/42 MAPK

Catalog number: 9102

Summary: Rabbit polyclonal antibody raised against a synthetic peptide corresponding to the C-terminal region of rat p44MAPK. Recognises total p44/42 MAPK. Supplier recommended for WB, IP, IHC, IF and flow cytometry. Reacts with human, mouse, rat, hamster, monkey, mink, bovine, Zebrafish, Sacharomyces cerevisiae and bovine p44/42 MAPK.

Validation Method

Western blot

Sample

Whole cell lysates of wild-type and Erk2 -/- (Erk2 = p42 MAPK) mouse embryonic stem cells.

Primary incubation

1:1000 dilution.

Secondary incubation

Peroxidase conjugated anti-rabbit IgG (Sigma, A6154) at 1:3000 dilution.

Detection

Super Signal West (Pierce).

Figure

See figure 4 from the article [1].

Disclaimer

If the antibody described in this summary is a polyclonal antibody, since polyclonal antibodies are of limited quantity, please inquire the supplier whether any current polyclonal antibody with the same catalog number is exactly the same as the one described in this summary. Sometimes, different bleeds or different animals are used, usually with a different lot number. In such cases, the result in this summary may not apply to the new antibody with the same catalog number.

References
  1. Kunath T, Saba-El-Leil M, Almousailleakh M, Wray J, Meloche S, Smith A. FGF stimulation of the Erk1/2 signalling cascade triggers transition of pluripotent embryonic stem cells from self-renewal to lineage commitment. Development. 2007;134:2895-902 pubmed